In response to RFA-CA-12-007, Community Clinical Oncology Program (CCOP), National Cancer Institute, the Carle Cancer Center located in Urbana, Illinois is applying for continued funding as an East Central Illinois CCOP. The Carle Cancer Center CCOP, consisting of a main base and two components, has been continually funded since the inception of the CCOP in 1983. Carle, now an integrated healthcare organization, brings together a research-driven network of healthcare services. At the core of this network reside the Carle Foundation Hospital, Carle Physician Group and Health Alliance Medical Plans. With a 325-bed Level I trauma hospital, over 300 physician group, and a self-owned health insurance product, the Carle CCOP possesses the resources necessary to further its research mission. Joining the Carle CCOP as component institutions are Rush-Copley Medical Center in Aurora, Illinois and Franciscan St. Anthony Health in Michigan City, Indiana. Altogether, the catchment area consists of over 4 million people of which 1.3 million are minorities. The CCOP's primary research base is located in Urbana, Illinois where all registration, randomization, quality assurance, and data management are conducted. The CCOP's primary research base affiliation is with Alliance. Additionally, the Carle Cancer Center CCOP is long-standing members of the Eastern Cooperative Oncology Group (ECOG), the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), the Gynecological Oncology Group (GOG), and the Cancer Trials Support Unit (CTSU). Additionally, this past spring, the Carle Cancer Center CCOP joined the SunCoast CCOP Research Base. The Carle CCOP has recently experienced a doubling of accrual and fully anticipates accrual rates of 468 treatment subjects and 703 cancer control subjects over the next five years. With a dedicated research team of 12 investigators, over 50 staff members, and interactive administrative support, the CCOP is well-positioned to succeed. Based on a research-driven culture, seasoned and engaged investigators, and impeccable regulatory standards, the Carle CCOP is positioned to provide the highest level of care to the communities it serves.
The Carle Cancer Center CCOP embraces the opportunity to participate in clinical trials that are designed to prevent cancer, control cancer related symptoms, and prolong disease-free survival in patients with diagnosed disease. The CCOP is committed to extending clinical trial opportunities to its predominantly rural population and increasing the research involvement of minority and underserved patient populations.
|Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85|
|Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:|
|Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55|
|Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80|
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
|Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76|
|Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83|
|Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7|
|Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27|
Showing the most recent 10 out of 164 publications